New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2013
08:38 EDTXNPT, BIIBXenoPort has positive readthroughs from clean Biogen label, says Wells Fargo
Wells Fargo believes that the benign FDA label for Biogen's (BIIB) Tecfidera indicates that regulators will have a favorable view of XenoPort's (XNPT) '829 treatment. The firm thinks that the label gives Biogen a better chance of maintaining exclusivity on its drug through 2028, possibly reducing the level of differentiation that XenoPort will need to demonstrate for '829. The firm maintains an Outperform rating on Xenoport.
News For XNPT;BIIB From The Last 14 Days
Check below for free stories on XNPT;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
July 21, 2014
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
July 9, 2014
07:23 EDTBIIBBiogen price target raised to $375 from $325 at RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use